Prospective evaluation of the feasibility of sentinel lymph node biopsy in breast cancer patients with negative axillary conversion after neoadjuvant chemotherapy by �븞�꽦洹� et al.
│ http://www.e-crt.org │26 Copyright ⓒ 2015 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2015;47(1):26-33
pISSN 1598-2998, eISSN 2005-9256
http://dx.doi.org/10.4143/crt.2013.208   
Open Access
Prospective Evaluation of the Feasibility of
Sentinel Lymph Node Biopsy in Breast Cancer Patients with
Negative Axillary Conversion after Neoadjuvant Chemotherapy
Purpose
Tumor response to neoadjuvant chemotherapy (NAC) may adversely affect the identification
and accuracy rate of sentinel lymph node biopsy (SLNB). This study was conducted to
evaluate the feasibility of SLNB in node-positive breast cancer patients with negative axillary
conversion after NAC. 
Materials and Methods
Ninety-six patients with positive nodes at presentation were prospectively enrolled.
18Fluorodeoxyglucose-positron emission tomography (18F-FDG PET) and ultrasonography
were performed before and after NAC. A metastatic axillary lymph node was defined as
positive if it was positive upon both 18F-FDG PET and ultrasonography, while it was consid-
ered negative if it was negative upon both 18F-FDG PET and ultrasonography.  
Results
After NAC, 55 cases (57.3%) became clinically node-negative, while 41 cases (42.7%)
remained node-positive. In the entire cohort, the sentinel lymph node (SLN) identification
and false-negative rates were 84.3% (81/96) and 18.4% (9/49), respectively. In the
negative axillary conversion group, the results of SLNB showed an 85.7% (48/55) identifi-
cation rate and 16.7% (4/24) false-negative rate. 
Conclusion
For breast cancer patients with clinically positive nodes at presentation, it is difficult to
conclude whether the SLN accurately represents the metastatic status of all axillary lymph
nodes, even after clinically negative node conversion following NAC.
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Introduction
Sentinel lymph node biopsy (SLNB) is now a standard
technique that has replaced axillary lymph node dissection
(ALND) for axillary staging in early breast cancer patients
that has resulted in much lower morbidity [1]. A sentinel
lymph node (SLN) identification rate of 97.2%, accuracy rate
of 97.1%, and false-negative rate (FNR) of 9.8% were reported
in a large multi-institutional randomized study [2]. If the
SLN is free of tumors following SLNB, the probability of
cancer cells in the remaining axillary nodes is assumed to be
less than 10%, in which case completion of ALND can be
omitted [3]. SLNB is currently recognized as a suitable
replacement for axillary dissection for staging procedures in
clinically node-negative T1 and T2 breast carcinomas [4].
Over the past decade, neoadjuvant chemotherapy (NAC)
has become increasingly common for the treatment of locally
advanced breast cancer [5]. However, the role of SLNB in
patients receiving NAC remains controversial. Nevertheless,
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meta-analysis for evaluation of the feasibility of SLNB after
NAC suggested that SLNB is a reliable tool for planning
treatment after preoperative chemotherapy [6]. Although
other small, single-institution investigations of the efficacy
of SLNB after NAC varied widely in identification rate and
FNR [7,8], recent analysis of larger and multicenter data sets
[9] revealed that SLNB after NAC seems to have a similar
performance outcome as SLNB before systemic therapy [10].
Additionally, a National Cancer Institute conference recently
reported that SLNB could be performed after NAC in
patients with clinically negative nodes at initial diagnosis
[11].  
However, it is still unclear if the inclusion of patients with
negative nodes at presentation for whom the results of SLNB
may not be affected by NAC is inappropriate for accurate
estimation of the predictive value of SLNB after NAC. Many
previous studies of SLNB after NAC included patients with
clinically negative nodes at presentation [12]; accordingly,
the FNR calculated in those studies may have been underes-
timated, resulting in the outcome being recognized as accept-
able when compared with SLNB before chemotherapy. As a
result, other investigators have launched trials that exclu-
sively enrolled patients with clinically positive nodes to
evaluate SLNB after chemotherapy [13-17]. 
Nevertheless, the argument against SLNB following NAC
has been made for patients with clinically positive nodes. As
shown in Fig. 1, the response to systemic therapy can differ
in each metastatic node, regardless of whether it is an SLN
or non-SLN. For these patients, the theory of SLNs, which is
postulated to be the first lymph node reached by metastasiz-
ing cancer cells from the tumor, could not be equally fitted.
In this study, we investigated node-positive breast cancer
patients with negative axillary conversion after NAC.
Patients with negative node conversion following NAC were
placed in the same context as clinically node-negative
patients. The primary goal of this study was to evaluate the
feasibility of SLNB in node-positive breast cancer patients
with negative axillary conversion after NAC in a prospective
clinical trial.
Materials and Methods
1. Patients and protocol
From January 2007 to December 2009, 96 patients with
T1-3 and documented axillary involvement at diagnosis were
prospectively enrolled at Gangnam Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea. An
overview of the study is provided in Fig. 2. Only patients
with axillary involvement upon initial presentation were
registered for this study. 
In this study, an accurate evaluation of the axillary lymph
node is crucial. In a previous report, we proposed that
combined evaluation of ultrasonography (US) and 18F-fluo-
rodeoxyglucose positron emission tomography (18F-FDG
PET) could increase the accuracy of axillary staging [18].
Evaluation of axillary nodal status using both modalities was
performed before and after chemotherapy in the present
study. US scans of axillary lymph nodes were evaluated for
shape, cortical thickening, and morphology of the hilum. A
finding was considered positive if 1) the cortex of the nodes
was concentrically or eccentrically thickened by more than 3
mm; 2) the node showed compression of the hilum and
absence of the fatty hilum; or 3) a length-to-width ratio less
than 1.5 was observed. If the axillary lymph nodes exhibited
any of these characteristics, they were defined as suspicious
for axillary lymph node metastasis. Nodes that exhibited
Fig. 1. Various treatment outcomes according to axillary
node status reflect an uneven tumor response to chemo-
therapy by each metastatic lymph node. Residual
non-sentinel node metastasis after chemotherapy could
raise concerns regarding application of sentinel lymph
node (SLN) biopsy for patients receiving neoadjuvant
chemotherapy (red arrow). 
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none of the three characteristics mentioned above were
defined as negative for axillary lymph node metastasis. Upon
evaluation of 18F-FDG PET images, if the quantitative meas-
urement of the single-pixel maximal standardized uptake
value (SUVmax) was  2.0 in the ipsilateral axillary lymph
node-bearing area it was considered positive for lymph node
metastasis. 
Nodes were considered clinically positive if the results of
axillary evaluation showed positive results upon both US
and 18F-FDG PET, regardless of palpable lymphadenopathy.
After NAC, the patients were re-evaluated using these
imaging studies. Patients with negative results following
both exams were defined as the negative axillary conversion
group. Patients with a positive node in any exam were
defined as the remaining positive group. 
All patients underwent complete ALND after SLNB for the
axillary operation. Patients diagnosed with inflammatory
breast cancer, T4, or who received palliative chemotherapy
due to metastatic breast cancer were excluded. This study
was prospectively initiated after approval from local institu-
tional review boards. Informed consent was obtained from
each participant in this study. This trial is registered with
ClinicalTrials.gov number, NCT01622478. 
2. Axillary lymph node mapping method
We conducted lymphatic mapping using technetium-99m
(99mTc) tin colloid. Intradermal injection of 0.4 mL 30 MBq (0.8
mCi) 99mTc tin colloid diluted in normal saline solution was
performed in 3-4 subareolar and intradermal areas. SLNs
were determined by employing a gamma camera in the
operating room (Gamma Detection System, Neoprobe
Corporation, Dublin, OH). The node showing the highest
radioactivity was dissected, after which the gamma detector
was used again to confirm the correct node. All radioactive
nodes with a count equal to or greater than 10% of the
highest radioactive node were removed. If nodes could not
be identified by the gamma probe, we proceeded with
ALND.
3. Pathological evaluation of SLN
SLNs larger than 0.5 cm in the maximal dimension were
serially sectioned transversely at 2-mm intervals, while those
smaller than 0.5 cm were bisected. The dissected lymph
nodes were measured and frozen, after which 4-µm serial
sections were prepared from a portion of the dissected
lymph node. Following pathologic evaluation of the sections,
the remaining tissue was fixed in 10% formalin, embedded
in paraffin blocks, and subjected to hematoxylin and eosin
staining. If the hematoxylin and eosin sections were negative
for malignancy, other sections were cut and immunohisto-
chemically stained for keratin using monoclonal anti-human
cytokeratin (clone AE1/AE3, Dako, Carpinetria, CA).
However, we did not consider cytokeratin-only SLN as
metastatic nodes because the clinical significance of
micrometastases detected by immunohistochemical exami-
nation is unclear [19].
4. Statistical analysis
The primary measurement was FNR in the negative
axillary conversion group. Baseline characteristics were
statistically analyzed with 2 or Fisher exact tests. The
nonparametric Mann-Whitney U test was used to compare
the number of resected SLNs. We compared the identifica-
tion rate, FNR, negative predictive value (NPV), and accu-
Breast cancer patients with
suspicious axillary lymph nodes
Axillary evaluaion using
18F-FDG PET and US
Axillary evaluaion using
18F-FDG PET and US
after chemotherapy
55 Patients with
negative axillary
conversion
41 Patients with
remaining positive node
96 Patients with known axillary involvement
at diagnosis
Neoadjuvant chemotherapy
Complete ALND after SLNB
Fig. 2. Study overview. 18F-FDG PET, 18Fluorodeoxyglu-
cose-positron emission tomography; US, ultrasonography;
ALND, axillary lymph node dissection; SLNB, sentinel
lymph node biopsy.
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Table 2. Results of sentinel lymph node biopsy
All patients Negative conversion Remaining positive p-valuec)(n=96)a),b) group (n=55)a),b) group (n =41)a),b)
Median No. of removed SLNs (range) 2 (1-7) 2 (1-6) 2 (1-7) 0.524
Identification rate 84.3 (81/96) 87.3 (48/55) 80.5 (33/41) 0.365
False-negative rate 18.4 (9/49) 16.7 (4/24) 20.0 (5/25) 0.763
Negative predictive value 78.0 (32/41) 85.7 (24/28) 61.5 (8/13) 0.082
Accuracy rate 87.9 (72/81) 91.7 (44/48) 82.8 (28/33) 0.337
SLN, sentinel lymph node. a)Percentage, b)Values in parentheses are fractions, c)Chi-squared test. 
Table 1. Baseline characteristics 
All patients Negative conversion Remaining p-valuea)(n=96) group (n=55) positive group (n =41)
Mean age (yr) 44.9±8.4 44.7±8.1 45.6±8.8 0.741b)
Mean tumor size prior to chemotherapyc) 2.9±1.6 2.7±1.5 3.2±1.8 0.161b)
Clinical nodal stage 0.535
N1 38 (40) 24 (44) 14 (34)
N2 51 (53) 28 (51) 23 (56)
N3 7 (7) 3 (5) 4 (10)
Regimen of chemotherapy 0.725
AT 72 (75) 42 (76) 30 (73)
CAF 17 (18) 10 (19) 7 (17)
AC 7 (7) 3 (5) 4 (10)
Surgery 0.038
Breast conservation 13 (14) 11 (20) 2 (5)
Mastectomy 83 (86) 44 (80) 39 (95)
Mean pathologic tumor size
after chemotherapy  1.5±1.3 1.3±1.2 1.6±1.5 0.364b)
Number of metastatic lymph nodes 0.102
Negative 37 (39) 27 (49) 10 (24)
1-3 39 (41) 19 (35) 20 (49)
4-9 14 (15) 6 (11) 8 (20)
10 6 (5) 3 (5) 3 (7)
pCRd) 0.990
Yes 14 (15) 8 (15) 6 (15)
Estrogen receptor 0.702
Positive 49 (51) 29 (53) 20 (49)
Progesterone receptor 0.783
Positive 39 (41) 23 (42) 16 (39)
HER-2 0.838
3 Positive or FISH amplification 41 (43) 23 (42) 18 (44)
AT, adriamycin-docetaxel; CAF, cyclophosphamide-adriamycin-5-fluorouracil; AC, adriamycin cyclophosphamide; pCR,
pathological complete response; HER-2, human epidermal growth receptor-2; FISH, fluorescence in situ hybridization.
a)Chi-squared test, b)Student’s t-test, c)Tumor size was measured by ultrasonography, d)pCR was defined as no evidence of
residual invasive cancer in both the breast and axilla.
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Table 3. Pathologic status of sentinel and axillary lymph nodes in the negative conversion groupa)
Axillary lymph nodeb)
SLNs
Positive Negative Total
Positive 20 (TP) 0 20
Negative 4 (FN) 24 (TN) 28
Total 24 24 -
SLN, sentinel lymph node; TP, true positive; FN, false negative; TN, true negative; FP, false positive. a)Fifty-five patients 
underwent a complete axillary lymph node dissection (excluding eight patients who did not have SLNs identified=48 evaluable
patients), b)Sensitivity: TP/(TP+FN)=14/18=77.8%; specificity: TN/(TN+FP)=24/24=100%; positive predictive value:
TP/(TP+FP)=20/20=100%; negative predictive value: TN/(TN+FN)=24/28=61.5%; overall accuracy: (TP+TN)/number of 
patients=(20+24)/48=91.7%; false-negative rate: FN/(TP+FN)=4/(20+4)=16.7%.
racy rate between the two groups using the 2 test. A 22 con-
tingency table was constructed to evaluate the feasibility of
SLNB in the negative axillary conversion group. p-values
were two-tailed, and values < 0.05 were considered to be
statistically significant. Analyses were conducted using SPSS
ver. 16.0 (SPSS Inc., Chicago, IL). 
Results
1. Patient characteristics 
There were 55 patients in the negative axillary conversion
group and 41 patients in the remaining positive group.
Mortality did not occur during chemotherapy. Pathologic
complete response (pCR) was defined as no evidence of
residual invasive cancer, both in the breast and axilla. The
rate of pCR in all patients was 14.6% (14 of 96).
The baseline characteristics of the two groups are summa-
rized in Table 1. No significant differences between groups
were observed prior to NAC. Similarly, except for the
proportion of surgical methods, no significant differences
were found in characteristics related to surgical outcome
including pathologic tumor size, rate of pCR, estrogen recep-
tor status, progesterone receptor status, and human epider-
mal growth receptor-2 status. The proportion of breast
conservation surgery was higher in the negative axillary
conversion group (20.0% vs. 4.8%, p=0.035).
2. Results of SLNB
The results of SLNB for all patients and the two groups are
listed in Table 2. For all patients, the median number of
identified SLNs was 2 (range, 1 to 7), and lymphatic mapping
was successful in 81 patients (84.3%, 81 of 96). FNR, NPV,
and the accuracy rate were calculated to be 18.4% (9 of 49),
78.0% (32 of 41), and 87.9% (72 of 81), respectively. 
The negative axillary conversion group showed an identi-
fication rate of 85.7% (48 of 56), a FNR of 16.7% (4 of 24), a
NPV of 85.7% (24 of 28), and an accuracy rate of 91.7% (44 of
48). There was no significant difference in SLNB values
Table 4. Characteristics of patients with a false-negative result following sentinel lymph node (SLN) biopsy in the clinically
negative node group after neoadjuvant chemotherapy (NAC)
Patient Age Tumor size Regimen of Type of Pathologic No. of Fraction of Size of a
No. (yr) before NAC chemotherapy surgery tumor size removed axillary metastatic node (cm) (cm) SLNs metastasis (mm)
1 49 3.6 AT Mastectomy 2 2 1/15 2 
2 39 2.4 CAF Mastectomy 2.2 6 1/22 2.2 
3 45 4.0 AT Mastectomy CR 1 1/10 2.1 
4 59 1.6 CAF Mastectomy CR 2 1/13 3
AT, adriamycin-docetaxel; CAF, cyclophosphamide-adriamycin-5-fluorouracil; CR, complete response.
Cancer Res Treat. 2015;47(1):26-33
30 CANCER  RESEARCH  AND  TREATMENT
between subgroups. A 22 contingency table for the negative
axillary conversion group was constructed to evaluate the
feasibility of SLNB (Table 3). The parameters of SLNB are
detailed in the footnotes to Table 3.
The characteristics of the four false-negative patients in the
negative axillary conversion group are presented in Table 4.
All patients underwent mastectomy. Two patients received
chemotherapy consisting of the adriamycin-docetaxel
regimen, while the others received the adriamycin-cycl-
ophosphamide regimen. The actual number of metastatic
lymph nodes was one in all patients, but the maximum
dimension of metastatic focus in non-SLN was larger than 
2 mm, indicating macrometastasis.
Discussion
When studies to evaluate the feasibility of SLNB following
NAC were designed, there was disagreement regarding
whether patients with clinically negative nodes should be
included. The results of SLNB may not be affected by
chemotherapy in patients with negative nodes at presenta-
tion. Therefore, it is necessary to conduct studies of patient
that had clinically positive nodes before NAC to evaluate
SLNB after chemotherapy. Previous studies of SLNB after
NAC for patients with clinically positive nodes at presenta-
tion reported identification rates of 77.6% to 98.0% and FNRs
of 5.6% to 25% [13-15]. Our findings of these parameters for
all patients showed results in the mid-range of these previ-
ous numbers, with an SLN identification rate of 84.3% and
an FNR of 18.4, which are too high to justify use of SLNB
after NAC. Otherwise, these studies included patients with
clinically positive nodes after NAC, in whom SLNB are not
indicated by the current treatment guideline [20]. Therefore,
a systematic protocol for re-evaluation of the axillary nodal
status following NAC is warranted.
Based on procedures commonly used in daily practice, we
defined positive nodes using only imaging modalities
because fine needle aspiration biopsy for axillary staging is
not routinely recommended during diagnostic work-ups. To
improve the accuracy of axillary staging without pathologi-
cal confirmation, we used combined imaging modalities of
18F-FDG PET and US. Gil-Rendo et al. [21] reported that
18F-FDG PET could be used to assess axillary status accu-
rately with a positive predictive value of 98.4% in another
prospective study.   
Another background characteristic of this study is the
uneven response to chemotherapy by each metastatic node.
As shown in Fig. 1, the tumor response to chemotherapy may
vary independently in each metastatic node. Therefore,
persistence of residual disease or undetected metastases in
non-SLNs may not be predicted by a negative finding from
SLNB, even in patients with a clinically negative axillary
status after systemic therapy. The uneven response to
chemotherapy is an important reason that many surgeons
are currently unable to establish a role for SLNB in patients
receiving NAC.
The use of SLNB is well established for patients with
clinically negative nodes upon initial diagnosis, and its use
contributes to axillary staging, expanding the opportunity to
spare the patient from ALND for early breast cancer. Several
reports have suggested that an FNR of 2% to 5% would be
reasonable to justify conducting SLNB [4,22]. Moreover,
expert panels have recommended that SLNB can be used to
replace formal axillary dissection in the majority of T1 and
T2 patients with clinically node-negative breast cancer when
surgeons consistently achieve a detection rate of 90% and an
FNR of 5% for representation of the entire axillary lymph
node status [4].
One important aspect that must be considered in clinical
practice is the need to identify a certain group with negative
axillary conversion after chemotherapy among patients with
positive nodes upon initial presentation. It is worth identify-
ing patients who are clinically node-positive after chemother-
apy in whom SLNB are not indicated by the current
treatment guidelines [20]. Therefore, we separated the
patients according to a nodal response, and mainly analyzed
the results of patients with negative node conversion. The
identification rate of SLN and FNR was 85.7% and 16.7%,
respectively, in these patients. This FNR was higher than the
expert panel’s recommendation and reasonable values of
FNR [4,22]. Knowing the exact pathologic staging acquired
by conventional surgery would be more valuable for
prognosis than other predictive models for patients follow-
ing NAC. Recent meta-analysis and pooled analysis based
on a neoadjuvant clinical trial suggested that pCR, defined
as no residuals in nodes or breasts, can best discriminate
between patients with favorable and unfavorable outcomes
[23,24]. These findings support the importance of axillary
staging for patients receiving NAC. Accordingly, the high
FNR with SLNB reported in our study raises concerns with
regard to the reliability of SLNB for patients with clinically
negative nodes after NAC.
Two large clinical trials to determine the accuracy of SLNB
in patients with clinically positive nodes were recently
reported. Specifically, an American College of Surgeons
Oncology Group Z1071 clinical trial (ACOSOG Z1071)
reported that SLNB after NAC in node-positive breast cancer
patients correctly identified nodal status in 84% of all
patients and that FNR was 12.8% in patients of clinical N1
with more than two resected SLNs [16]. The key difference
in their trial design and our study is that they omitted
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axillary reevaluation after NAC.
The results of the prospective German multi-institutional
SENTINA-trial (SENTINA) are more concordant with our
findings. In arm C of the SENTINA-trial, they enrolled
patients with clinically negative axillary conversion after
NAC based on the results of US. The rate of FNR in 592
patients was 14.2%. The investigators concluded that use of
SLNB as a diagnostic procedure is not a reliable tool in
patients who convert from clinical N1 to clinical N0 under
NAC when compared to SLNB during primary surgery [17].
It should be noted that this study has several limitations.
For example, there was a small number of enrolled patients;
thus, the outcome was largely affected by a single event.
Moreover, the definition of clinically negative node status
was determined based on both 18F-FDG PET and US, which
made it difficult to enroll patients to the negative axillary
conversion group. Nevertheless, the results of this study
have clinical significance and provide important insight into
the validation of SLNB following NAC.
In future studies, subgroups of positive node breast cancer
patients with negative axillary conversion who are safely
eligible for SLNB should be identified. Resection of at least
three SLNs and adoption of dual tracers that were suggested
by the two prospective trials will be useful in identification
of suitable subgroups.
Conclusion
Overall, the results of this study indicate that routine use
of SLNB is not feasible for patients who undergo NAC, even
after clinically negative node conversion following NAC. 
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